Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

[Disseminated intravascular coagulation].

Toshiaki Iba1, Akio Kidokoro

  • 1Department of Surgery, Juntendo University, Urayasu Hospital.

Nihon Rinsho. Japanese Journal of Clinical Medicine
|June 17, 2003
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Response to the comment by Gando on the updated definition and scoring of disseminated intravascular coagulation.

Journal of thrombosis and haemostasis : JTH·2026
Same author

Designing biomarker-selected international trials in sepsis-associated coagulopathy.

Journal of thrombosis and haemostasis : JTH·2026
Same author

Precision medicine in sepsis: lessons from the TIGRIS trial and the reawakening of targeted therapy.

Journal of anesthesia, analgesia and critical care·2026
Same author

Regulated cell death in sepsis: reframing NETosis within the spectrum of apoptosis and inflammatory lytic death.

Inflammation research : official journal of the European Histamine Research Society ... [et al.]·2026
Same author

Redefining Fibrinolytic Insufficiency in Sepsis-Associated DIC.

Seminars in thrombosis and hemostasis·2026
Same author

Anaphylaxis and coagulopathy: from rare case reports to mechanistic insights.

Journal of thrombosis and haemostasis : JTH·2026
Same journal

[Development of novel therapeutics for multiple myeloma and improvement of drug lag].

Nihon rinsho. Japanese journal of clinical medicine·2019
Same journal

[Clinical pharmacy services to patients of immunomodulatory drugs].

Nihon rinsho. Japanese journal of clinical medicine·2019
Same journal

[Therapeutic drug monitoring of the new anti-myeloma drugs in the treatment of multiple myeloma].

Nihon rinsho. Japanese journal of clinical medicine·2019
Same journal

[Prognostic value of minimal residual disease assessment using next-generation sequencing in multiple myeloma].

Nihon rinsho. Japanese journal of clinical medicine·2019
Same journal

[The evaluation of minimal residual disease in multiple myeloma by an allele-specific oligonucleotide real-time PCR].

Nihon rinsho. Japanese journal of clinical medicine·2019
Same journal

[Evaluation of minimal residual disease in myeloma by multiparametric flow cytometry].

Nihon rinsho. Japanese journal of clinical medicine·2019
See all related articles

Disseminated intravascular coagulation (DIC), often caused by cancer, involves dangerous blood clotting. Treatment choices vary by underlying cause, impacting bleeding and organ function.

Area of Science:

  • Hematology
  • Oncology
  • Pathophysiology

Context:

  • Disseminated intravascular coagulation (DIC) is a serious acquired condition.
  • Cancer is a primary cause of DIC, leading to bleeding and organ dysfunction.
  • Effective DIC management is crucial for patient quality of life.

Purpose:

  • To outline current therapeutic options for DIC.
  • To emphasize the importance of understanding individual pathophysiology for treatment selection.
  • To guide drug selection based on DIC subtype (fibrinolysis vs. coagulation dominant).

Summary:

  • DIC involves systemic microthrombi and fibrin deposition.
  • Treatment options include heparin, low molecular weight heparin, danaparoid, protease inhibitors, and antithrombin III.

Related Experiment Videos

  • Protease inhibitors are recommended for fibrinolysis-dominant DIC (e.g., leukemia, advanced solid cancers).
  • Danaparoid and antithrombin III are preferred for coagulation-dominant DIC (e.g., sepsis).
  • Platelet and fresh frozen plasma supplementation should be judiciously used.

    • Impact:

    • Informed treatment decisions for DIC patients.
    • Improved management of bleeding complications in cancer patients.
    • Enhanced understanding of DIC subtypes and targeted therapies.